Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
Provided By GlobeNewswire
Last update: Jun 23, 2025
Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies
Top-line data expected in the first quarter of 2026
Read more at globenewswire.com
